High-density lipoprotein therapy inhibits Porphyromonas gingivalis-induced abdominal aortic aneurysm progression

Summary

Clinical and experimental studies have highlighted the potential implication of periondontal bacteria contamination in the pathogenesis of abdominal aortic aneurysms (AAA). In addition to their role in reverse cholesterol transport, high-density lipoproteins (HDLs) display multiple functions, including anti-inflammatory and lipopolysaccharide scavenging properties. Low plasma levels of HDL-cholesterol have been reported in AAA patients. We tested the effect of a HDL therapy in Sprague-Dawley rat model of AAA, obtained by intraluminal elastase infusion followed by repeated injections of Porphyromonas gingivalis (Pg). HDLs, isolated by ultracentrifugation of plasma from healthy human volunteers, were co-injected intravenously (10 mg/kg) with Pg (1.10⁷ Colony Forming Unit) one, eight and 15 days after elastase perfusion. Rats were sacrificed one week after the last injection. Our results show that Pg injections promote the formation of a persistent neutrophil-rich thrombus associated with increased aortic diameter in this AAA model. HDLs significantly reduced the increased AAA diameter induced by Pg. Histology showed the onset of a healing process in the Pg/HDL group. HDL injections also reduced neutrophil activation in Pg-injected rats associated with decreased cytokine levels in conditioned media and plasma. Scintigraphic analysis showed an intense uptake of ⁹⁹mTc-HDL by the AAA suggesting that HDLs could exert their beneficial effect by acting directly on the thrombus components. HDL supplementation may therefore constitute a new therapeutic tool for AAA treatment.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Abdominal aortic aneurysm - high-density lipoproteins - Poprhyromonas gingivalis - neutrophils

• References

• 1 Michel JB, Martin-Ventura JL, Egido J. et al. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 2011; 90: 18-27.
• 2 Michel JB, Thaunat O, Houard X. et al. Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007; 27: 1259-1268.
• 3 Gaetti-Jardim Jr. E, Marcelino SL, Feitosa AC. et al. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol 2009; 58: 1568-1575.
• 4 Nakano K, Nishinaka K, Tanaka T. et al. Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography. J Virol Methods 2009; 161: 223-230.
• 5 Hanaoka Y, Soejima H, Yasuda O. et al. Level of serum antibody against a periodontal pathogen is associated with atherosclerosis and hypertension. Hypertens Res 2013; 36: 829-833.
• 6 Delbosc S, Alsac JM, Journe C. et al. Porphyromonas gingivalis participates in pathogenesis of human abdominal aortic aneurysm by neutrophil activation. Proof of concept in rats. PLoS One 2011; 6: e18679.
• 7 Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17: 594-603.
• 8 de Haas CJ, Poppelier MJ, van Kessel KP. et al. Serum amyloid P component prevents high-density lipoprotein-mediated neutralisation of lipopolysaccharide. Infect Immun 2000; 68: 4954-4960.
• 9 Golledge J, van Bockxmeer F, Jamrozik K. et al. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010; 105: 1480-1484.
• 10 Torsney E, Pirianov G, Charolidi N. et al. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2012; 32: 2678-2686.
• 11 Krishna SM, Seto SW, Moxon JV. et al. Fenofibrate increases high-density lipo-protein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol 2012; 181: 706-718.
• 12 Anidjar S, Salzmann JL, Gentric D. et al. Elastase-induced experimental aneurysms in rats. Circulation 1990; 82: 973-981.
• 13 Delbosc S, Rouer M, Alsac JM. et al. Elastase inhibitor AZD9668 treatment prevented progression of experimental abdominal aortic aneurysms. J Vasc Surg. 2014 Epub ahead of print.
• 14 Delbosc S, Diallo D, Dejouvencel T. et al. Impaired high-density lipoprotein anti-oxidant capacity in human abdominal aortic aneurysm. Cardiovasc Res 2013; 100: 307-315.
• 15 Atsma DE, Feitsma RI, Camps J. et al. Potential of 99mTc-LDLs labelled by two different methods for scintigraphic detection of experimental atherosclerosis in rabbits. Arterioscler Thromb 1993; 13: 78-83.
• 16 Johnston WF, Salmon M, Su G. et al. Genetic and pharmacologic disruption of interleukin-1beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2013; 33: 294-304.
• 17 Yates CM, Abdelhamid M, Adam DJ. et al. Endovascular aneurysm repair reverses the increased titer and the inflammatory activity of interleukin-1alpha in the serum of patients with abdominal aortic aneurysm. J Vasc Surg 2011; 54: 497-503.
• 18 Schonbeck U, Sukhova GK, Gerdes N. et al. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002; 161: 499-506.
• 19 Flondell-Site D, Lindblad B, Kolbel T. et al. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokine 2009; 46: 211-215.
• 20 Newman KM, Jean-Claude J, Li H. et al. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 1994; 90: II224-227.
• 21 Middleton RK, Lloyd GM, Bown MJ. et al. The pro-inflammatory and chemot-actic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007; 45: 574-580.
• 22 Bergt C, Pennathur S, Fu X. et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004; 101: 13032-13037.
• 23 Hadfield KA, Pattison DI, Brown BE. et al. Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density Lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). Biochem J 2013; 449: 531-542.
• 24 Ortiz-Munoz G, Houard X, Martin-Ventura JL. et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009; 23: 3129-3139.
• 25 Murphy AJ, Woollard KJ, Suhartoyo A. et al. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 1333-1341.
• 26 Bao Dang Q, Lapergue B, Tran-Dinh A. et al. High-density lipoproteins limit neutrophil-induced damage to the blood-brain barrier in vitro. J Cereb Blood Flow Metab 2013; 33: 575-582.
• 27 Moreno JA, Ortega-Gomez A, Rubio-Navarro A. et al. High-Density Lipoproteins Potentiate alpha1-Antitrypsin Therapy in Elastase-Induced Pulmonary Emphysema. Am J Respir Cell Mol Biol 2014; 51: 536-549.
• 28 Gautier T, Lagrost L. Plasma PLTP (phospholipid-transfer protein): an emerging role in ‘reverse lipopolysaccharide transport’ and innate immunity. Biochem Soc Trans 2011; 39: 984-988.
• 29 Flegel WA, Wolpl A, Mannel DN. et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-2245.
• 30 Hailman E, Albers JJ, Wolfbauer G. et al. Neutralisation and transfer of lipopoly-saccharide by phospholipid transfer protein. J Biol Chem 1996; 271: 12172-12178.
• 31 Parker TS, Levine DM, Chang JC. et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63: 253-258.